Drug Delivery Business

  • Discovery
    • Technology
  • Research & Development
  • Preclinical Trials
  • Clinical Trials
  • Policy
  • Contract Services
  • Diagnostics

FDA rejects Novartis’ Advair generic, leaving GSK without rival

February 8, 2018 By Sarah Faulkner Leave a Comment

GlaxoSmithKlineGlaxoSmithKline (NYSE:GSK) was granted a temporary win today after Novartis‘ (NYSE:NVS) Sandoz unit reported that the FDA rejected its application for a generic version of the company’s blockbuster lung treatment, Advair.

The regulatory agency reportedly told Novartis that it needs to submit additional clinical data before the FDA can make its final decision.

GSK said in its earnings report yesterday that if there is no generic competition for Advair this year, its earnings could increase as much as 7%.

The pharma company’s Advair drug-device combination is designed for asthma patients ages 4 and older. The fluticasone propionate/salmeterol device also treats airflow obstruction and lessens exacerbations in patients with chronic obstructive pulmonary disorder.

Analysts expect that GSK’s Advair product will bring in more than $3B in sales this year, according to Bloomberg.

GSK shares jumped on the recently regulatory news, trading at $37.58 in pre-market activity today, up 4.4%. Meanwhile, NVS shares fell slightly, trading at $84.22 apiece before the market opened.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: GlaxoSmithKline plc, Novartis, sandoz

IN CASE YOU MISSED IT

  • Phillips-Medisize is expanding in Wisconsin
  • Cash-strapped Aradigm declares bankruptcy
  • Medtronic: Patient deaths left out of paclitaxel-coated balloon analysis
  • Teva aims for 25% of U.S. EpiPen market by 2020
  • Medtronic wins FDA’s breakthrough status for closed-loop insulin system

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookDrug Delivery Business News
Follow us on Twitter@DrugDeliveryNow
Connect with us on LinkedInLinkedIn

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS